Objective: To examine the efficacy and tolerability of rosuvastatin 5 mg at daily and non-daily
dosing regimens. Research design and methods: A retrospective survey was conducted at …

BACKGROUND: Many patients who could benefit from hydroxymethylglutaryl coenzyme-A
reductase inhibitors (statins) are unable to take statins because of myalgias while taking …

Statins possess an excellent safety profile and are generally well tolerated when
administered in the standard once-daily dosing regimen. A small percentage of patients …

The purpose of this study was to determine the efficacy of rosuvastatin dosed once a week in
patients with a previous statin adverse event. Rosuvastatin once a week was tolerated by 37 …

The aim of this study was to evaluate the efficacy of rosuvastatin twice weekly in 40 patients
intolerant to daily statins. Rosuvastatin twice weekly alone or added to other lipid-lowering …

BACKGROUND:: Patients with high levels of low-density lipoprotein cholesterol (LDL-C)
might not tolerate 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (“statins”) …

Background: The safety and tolerability of rosuvastatin were assessed using data from
16,876 patients who received rosuvastatin 5–40 mg in a multinational phase II/III/IIIb/IV …

Background: Although most patients with hypercholesterolemia require life-long therapy with
statins, these drugs are underused due to high costs. Every-other-day therapy could be one …

Background Rosuvastatin (Crestor), a new, highly efficacious statin, has demonstrated dose-
dependent low-density lipoprotein cholesterol (LDL-C) reductions of up to 65% in a dose …

Background: There is an increasing body of evidence to support the benefits of reducing low-
density lipoprotein cholesterol (LDL-C) levels and this has been reflected in a lowering of …